{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-247004","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.719870+00:00","generated_at":"2026-05-30T08:13:29.706109+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CalciMedica reports positive Phase 2b CARPO data: 100% reduction in severe respiratory failure with high-dose Auxora","bullets":["100% relative risk reduction (p=0.0027) in new-onset severe respiratory failure for combined high/medium dose vs low dose/placebo.","Stratified win ratio of 1.640 (p=0.0372) for high dose (2.0 mg/kg) Auxora vs placebo across key endpoints.","No drug-related serious adverse events or deaths at high dose; trend of decreasing TESAE rates with higher dose.","Planning end-of-Phase 2 meeting with FDA to design Phase 3 trial of Auxora in acute pancreatitis with SIRS.","Median time to medically indicated discharge reduced by 15 hours for high dose vs placebo (89 vs 104 hours)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-247004","json":"https://secwatch.observer/filing/0001193125-24-247004.json","markdown":"https://secwatch.observer/filing/0001193125-24-247004.md","text":"https://secwatch.observer/filing/0001193125-24-247004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312524247004/0001193125-24-247004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312524247004/d885957d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:13:29.706109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}